Chronic hepatitis C genotype 1 virus: Who should wait for treatment?

Table 2 New directly acting antivirals submitted to regulatory agencies

Ref	Phase	Drug	Gen	n	Status	PEG-IFN	RBV	SVR
Kowdley et al[62]	II	Sofosbuvir	1	316	Naïve	Y	Y	87%-89%
(ATOMIC)
Lawitz et al[63]	II	Sofosbuvir	1	122	Naïve	Y	Y	90%
			2, 3	25				92%
Gane et al[56]	IIa	Sofosbuvir	2, 3	40	Naïve	Y/N	Y/N	60%-100%
(ELECTRON)			1	35	Naïve/experienced	N	Y	10%-84%
Lawitz et al[64]	III	Sofosbuvir	1, 4, 5, 6	327	Naïve	Y	Y	90%
(NEUTRINO/FISSION)			2, 3	499	Naïve	N	Y	67%
Jacobson et al[65]	III	Sofosbuvir	2, 3	207	Naïve	N	Y	78%
(POSITRON/FUSION)			2, 3	103	Experienced			50%
Fried et al[51]	IIb	Simeprevir	1	388	Naïve	Y	Y	75%-86%
(PILLAR)
Zeuzem et al[54]	IIb	Simeprevir	1		Experienced	Y	Y	70%-96%
(ASPIRE)
Jacobson et al[66]	III	Simeprevir	1	394	Naïve	Y	Y	80%
(QUEST 1)
Manns et al[67]	III	Simeprevir	1	391	Naïve	Y	Y	81%
(QUEST 2)

Gen: Genotype; RBV: Ribavirin; PEG-IFN: Polyethylene glycol-interferon; Y: Yes; N: No; SVR: Sustained virological response.